DDInter875 DDInter7
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Abemaciclib may lead to a major life threatening interaction when taken with Troleandomycin
Abemaciclib may lead to a major life threatening interaction when taken with Fingolimod